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A HER2 selective theranostic agent for surgical resection guidance 
and photodynamic therapy. 
H. Pyea, M.A. Butta,b, H.W. Reinerta, A. Maruanic, J.P.M. Nunesc, J.S. Marklewd, M. Qurashia,e, L. 
Funnella, A. Maya, I. Stamatid, R. Hamoudia, J.R. Bakerc, M.E.B. Smithc, S. Caddickc, M.P Deonaraina,d,e, 
G. Yahioglud,e*, V. Chudasamac* and L.B. Lovata,b* 
In many cancers early intervention involves surgical resection of small localised tumour masses. Inadequate resection leads 
to recurrence whereas overzealous treatment can lead to organ damage. This work describes production of a HER2 targeting 
antibody Fab fragment dual conjugated to achieve both real time near-infrared fluorescent imaging and photodynamic 
therapy. The use of fluorescence emission from a NIR-dye could be used to guide resection of tumour bulk, for example 
during endoscopic diagnosis for oesophago-gastric adenocarcinoma, this would then be followed by activation of the 
photodynamic therapeutic agent to destroy untreated localised areas of cancer infiltration and tumour infiltrated lymph 
nodes. This theranostic agent was prepared from the Fab fragment of trastuzumab initially by functional disulfide re-bridging 
and site-specific click reaction of a NIR-dye. This was followed by further reaction with a novel pre-activated form of the 
photosensitiser chlorin e6 with the exposed fragments’ lysine residues. Specific binding of the theranostic agent was 
observed in vitro with a HER2 positive cell line and cellular near-infrared fluorescence was observed with flow cytometry. 
Specific photo-activity of the conjugates when exposed to laser light was observed with HER2 positive but not HER2 negative 
cell lines in vitro, this selectivity was not seen with the unconjugated drug. This theranostic agent demonstrates that two 
different photo-active functions can be coupled to the same antibody fragment with little interference to their independent 
activities. 
Introduction  
The Human Epidermal Growth Factor Receptor 2 (HER2) has 
no known ligand but can form heterodimers with other 
members of the family to initiate downstream signalling in 
cellular pathways that include proliferation, differentiation, 
angiogenesis and cell survival1. Attention was originally drawn 
to HER2 when it was shown that amplification at both the gene 
and protein level occur in about 20% of patients with breast 
cancer and correlated with poor prognosis2. HER2 is now 
implicated in many other cancers including bladder, pancreatic, 
lung, ovarian, endometrial, colorectal, renal, head and neck, 
gastric, oesophageal, and prostate cancers3.  
Overexpression of HER2 has been described in 
gastrointestinal (GI) cancers and was recently validated by our 
group as positive in 26% of upper oesophago-gastric 
adenocarcinoma (OGA) patients4–6. However, HER2 expression 
in OGA is heterogeneous and the link between overexpression 
and patient prognosis remains controversial due to study bias 
for cancer position or grade alongside subjective scoring and 
lack of technique standardisation across the field7–11. Imaging 
for this disease is minimally invasive and is performed using an 
endoscope. Similarly, abdominal surgery is increasingly being 
performed using laparoscopy. This represents an unique 
opportunity for the delivery and activation of light activated 
diagnostic tools and drugs. An estimated 8,000 new cases of 
oesophageal adenocarcinoma (OA) are diagnosed yearly in the 
UK with a 5-year survival of 15%. Tumours that present early 
can be treated by endoscopic resection however, despite high 
quality imaging tools, small tumours are hard to detect and 
even when intramucosal cancer is present visible lesions are 
only found in ~60% of cases6. Also visible tumours have 
indistinct edges and inadequate resection leads to recurrence 
whereas overzealous treatment leads to intractable 
oesophageal strictures. Better identification is needed to 
ensure appropriate treatment both endoscopically and during 
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surgery for larger lesions. Fluorescence imaging is a powerful 
approach already used in the clinical setting, as is PDT and both 
are compatible with endoscopy. Therefore a combined 
approach with more focused targeting and the potential for a 
‘see-and-treat’ modality would be very attractive and 
potentially straight-forward to implement into clinical practice 
for OA treatment. 
HER2 already provides a validated basis for targeted 
therapeutics and trastuzumab (HerceptinTM) is a humanised 
monoclonal immunoglobulin G (IgG) against HER2 which alone, 
and in combination therapy, has been used to successfully treat 
breast cancer12,13. The potential for trastuzumab therapy in GI 
cancers was shown in the ToGA (Trastuzumab for GAstric 
Cancer) clinical study14 leading to its approval for use with 
chemotherapy for patients with HER2-positive metastatic OGA. 
The mechanism of resistance to trastuzumab in breast cancer is 
complex and related to signalling defects rather than receptor 
down-regulation15. This makes an antibody–drug conjugate 
(ADC) approach attractive for the delivery of cytotoxins directly 
to the tumour. The most successful ADC to date is trastuzumab 
emtansine (KadcylaTM,), for treating HER2-positive metastatic 
breast cancer16. 
Generally, whole antibody formats, such as IgG are retained 
at high levels in human tumours over longer time periods (days–
weeks), but with a lower degree of specificity, their slow 
penetration means that it takes days for significant levels to 
accumulate in tumours whilst the Fc-domain leads to significant 
cross-reaction with normal tissues, especially the liver17. 
Smaller fragments, e.g. Fab and scFv are taken up by the tumour 
more rapidly (within hours as elegantly demonstrated by Denis 
et al.18) but at comparatively lower levels and with quicker 
serum and tumour clearance times19,20. This leads to a higher 
tumour:normal tissue ratio (specificity) which is important for 
both a therapeutic agent (side-effects) and an imaging agent 
(contrast)21.  
The use of site-selective antibody conjugation is known to 
generate well-characterised, homogeneous and reproducible 
antibody conjugates that behave predictably in vivo22. Next-
generation maleimides and pyridazinediones are intrinsically 
more stable than conventional maleimide conjugates which can 
suffer from oxidative loss of payload. Furthermore, the 
technology can be manipulated to create thiol-stable, acid 
cleavable or thiol cleavable linkers, as well as target exposed 
cysteine residues or disulfide bonds as sites for conjugation23–
31. Previous relevant application of the technology include bi-
functional antibody bioconjugation and photosensitiser 
conjugation to trastuzumab32–34.  
Photodynamic therapy (PDT) is an approved treatment 
modality for cancer. This approach involves administration of 
photosensitisers (PS) which accumulate passively in the tumour 
and are locally activated using laser light. Subsequent cellular 
destruction occurs via reactive oxygen species (ROS) and/or 
free radicals35–37. This approach is a treatment for localised light 
accessible solid tumours without the toxicity and collateral 
damage associated with radiotherapy or major surgery. PDT can 
also activate an immune response to cancer, a key step in 
establishing a prolonged remission38–41. However, a limitation 
of PDT is its poor tumour selectivity and a suboptimal 
pharmacokinetic / biodistribution profile. This leads to low 
potency and prolonged skin photosensitivity which can lead to 
severe ‘sunburn’ as well as the development of scarring and 
structuring of internal organs including the oesophagus42. This 
has hindered the acceptance of this powerful treatment as a 
standard cancer treatment modality. Antibody-based 
photodynamic therapy, in particular with antibody fragments, 
aims to overcome these problems by reducing non-specific 
uptake of PS and improve PS clearance rates43–46. We have 
previously demonstrated that HER2-expressing tumours can be 
eradicated in vivo using an scFv conjugated to the PS 
pyropheophorbide-a, but this PS did not have a useful imaging 
read-out making it unattractive as a potential theranostic44. 
Further development of this as a PDT agent only and not a 
theranostic will be published elsewhere. 
The targeting vehicle for our theranostic approach herein is 
based on a trastuzumab Fab fragment. Fab molecules still 
maintain all the pharmacokinetic benefits of smaller antibody 
fragments but can cope with higher drug loading due to their 
slightly larger size, the presence of a disulphide bond also lends 
itself better than an ScFv to the application of two different 
conjugation techniques. The Fab was prepared to a high quality 
from the parent molecule using sequential enzyme digest. An 
endogenous disulphide was replaced using an alkyne-bearing 
next-generation maleimide. This alkyne allowed the efficient 
conjugation of an azide-containing NIR-dye (IR Dye 800 CW) to 
the Fab through highly specific ‘click’ chemistry resulting in an 
exceptionally pure product with one bright NIR-dye molecule 
covalently attached to each Fab molecule. This commercial NIR 
dye was chosen due to its high quality, the fact it is 
manufactured under cGMP and because it is already 
undergoing multiple clinical trials in an ADC form47. Chlorin e6 
was chosen as the PS because it is a well studied PS with high 
water solubility and high singlet oxygen yield48. Its initial 
conjugation to the functionalised Fab fragment was attempted 
through classical acyl urea chemistry involving activation of one 
of the carboxylic acid residues using N-hydroxysuccinimide and 
a carbodiimide dehydrating agent, but with limited success due 
to the multifunctional nature of chlorin e6. A cleaner and more 
efficient conjugation was achieved using a pre-activated 
anhydride form of chlorin e6 which reacts with surface lysine 
residues through selective ring opening resulting in amide bond 
formation but without the crosslinking seen with the in situ 
carbodiimide conjugation approach. The PS and NIR dye 
components were specifically chosen so that the absorbance 
spectrum of the PS was as far into the red as possible to allow 
deeper light penetration and an optical spectrum that was not 
interfered by the excitation and imaging of the NIR dye. The 
chemistries for the conjugation were chosen to be bi-
orthogonal and compatible for commercial application. The 
resulting theranostic antibody fragment (Fab-NIR-PS) was 
shown to be applicable to NIR fluorescence cell-labelling of 
HER2 positive oesophageal adenocarcinoma cells in vitro. It was 
also tested in an in vitro model of PDT in which it exhibited 
improved PDT cytotoxicity and HER2-expressing cell specificity 
compared to the equivalent unconjugated PDT drug. 
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Results and Discussion 
Production of trastuzumab Fab alkyne 
To produce high purity trastuzumab Fab alkyne, high quality 
trastuzumab IgG (Roche) underwent sequential enzymatic 
digest; the most common glycoform of trastuzumab IgG is 
148059 Da49. LC-MS demonstrated that the pepsin digested 
trastuzumab-F(ab’)2, had an observed mass of 97303 Da. The 
trastuzumab-F(ab’)2 fragment was further digested with papain 
to obtain the Fab fragment with an observed mass of 47635 Da 
by Agilent LC-MS. The interchain disulfide was reduced using 
TCEP and the purified fragment was analysed by Agilent LC-MS 
with observed masses of 24200 Da and 23439 Da to reveal the 
heavy and light chains only, thus confirming that fully reduced 
trastuzumab Fab had been produced. The reduced trastuzumab 
Fab was then re-bridged using a bridging agent (N-propargyl-
3,4-dibromomaleimide) that permits site-specific and 
stoichiometric (1:1) introduction of a single alkyne functional 
group onto the Fab fragment with a yield of 96%50. Non-
reducing SDS-PAGE and Agilent LC-MS analysis (Fig. 1) 
confirmed the protein was pure and of the expected molecular 
weight with an LC-MS observed mass of 47785 Da compared to 
the expected mass of 47786 Da. (More detail in Supplementary 
data). 
Selective binding of trastuzumab Fab-alkyne to HER2 positive cells 
To investigate the ability of the modified antibody to bind to 
cells in vitro, trastuzumab Fab-alkyne was analysed by flow 
cytometry with two different cell lines. OE19 is a HER2 positive 
human epithelial cell line established from a stage three 
moderately differentiated OGA, and was recently validated 
against the original pathology sample51,52. U-87 (U-87 MG) is a 
human glial cell line established from a grade IV glioblastoma of 
the brain53 and was used as a negative control for HER2 
expression. A FITC conjugated secondary antibody was used to 
detect any trastuzumab bound to cells (Fig. 2). With OE19 cells 
both the trastuzumab IgG and the trastuzumab Fab-alkyne 
showed a dose-dependant increase in the fluorescence signal. 
Saturation of the fluorescence signal indicated cell surface 
 
 
Fig 1.Characterisation of trastuzumab Fab-alkyne on (A) an Agilent system LC-MS 
and shows a pure product of the predicted molecular weight; data deconvoluted. 
(B) Non-reducing SDS-PAGE data stained with Coomassie. Picture insert (C) shows 
the chemical detail of the modified disulphide bridging within the antibody 
fragment 
expression. A FITC conjugated secondary antibody was used to 
detect any trastuzumab bound to cells (Fig. 2). With OE19 cells 
both the trastuzumab IgG and the trastuzumab Fab-alkyne 
showed a dose-dependant increase in the fluorescence signal. 
Saturation of the fluorescence signal indicated cell surface 
receptor saturation. With the Fab-alkyne very little binding 
affinity was lost compared to the native IgG despite the loss of 
the avidity effect. (NB no change in binding affinity was seen 
between Fab and Fab-alkyne). Nonlinear regression analysis 
using standard 2-parameter, 1:1 binding equations allowed an 
estimation of the dissociation constant Kd for these antibodies 
on this cell line which were as follows; trastuzumab IgG Kd = 
11.8nM, trastuzumab Fab-alkyne Kd = 43.7 nM. There was no 
non-specific cell binding of either antibody format to the HER2 
negative line. Trastuzumab IgG and trastuzumab Fab-alkyne 
also bound specifically to other HER2 positive human 
gastrointestinal tract adenocarcinomas including, OE33 an 
oesophageal cancer line and NCI-N87 a gastric cancer line 
(Supplementary data).Using the functional re-bridging of a 
native interchain disulfide bond, a non-native reactive chemical 
alkyne group was introduced away from the antibody binding 
site which preserved the structural integrity of the molecule 
while providing a stable covalently bound alkyne group at 1:1 
stoichiometry in 100% of the molecules reacted. 
 
 
Fig 2. Binding of trastuzumab Fab-alkyne compared to its parent molecule 
trastuzumab IgG onto a HER2 positive oesophageal adenocarcinoma cell line 
(OE19) using flow cytometry (A). An increase in fluorescence represents more 
trastuzumab has bound to each cell and the saturation of the fluorescent signal 
indicates cell surface receptor saturation. Very little binding affinity is lost in the 
Fab despite the loss of bi-valency. Neither version bound the human glioblastoma 
cell line U87 (control for HER2 negativity) (B). Binding to the HER2 positive line 
was quantified using the geometric means of the fluorescent shift curves. This is 
shown in (C) with nonlinear regression analysis fitted to a 1:1 binding isotherm to 
calculate the dissociation constant Kd; Equation fitted as follows (f = 
Bmax*abs(x)/(Kd + abs(x)). Trastuzumab IgG Kd = 11.8 nM, trastuzumab Fab-
alkyne Kd = 43.7 nM. 
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Formation of the Fab-NIR dye conjugate 
To add the imaging agent a near-infrared (NIR) dye, IR Dye 
800 CW (LiCOR), carrying an azide functional group was linked 
on the alkyne functionalised Fab fragment using bio-compatible 
click chemistry54: (supplementary data). A small proportion of 
protein was lost upon purification resulting in a yield of ~85%. 
Samples of the ‘Fab-NIR’ imaging agent were taken throughout 
the purification process for analyses and quality control on SDS-
PAGE (Fig. 3a, 3b). These showed that unconjugated NIR dye 
was successfully removed from the final product by desalting. 
In the post-conjugation samples NIR dye fluorescence was seen 
co-localised with the protein band at ~48 kDa demonstrating 
the conjugation is covalent. The conjugated Fab migrated at a 
slightly higher MW compared to the Fab alone due to the 
addition of the dye. 
To calculate the efficiency of the ‘click’ reaction a diluted 
sample of Fab-NIR was analysed by UV-Vis spectroscopy (Fig. 
3c). Extinction coefficients of the free dye and protein were 
used to determine the dye and protein concentrations of the 
conjugate. The protein absorption at 280nm was corrected for 
NIRdye and it was assumed that absorbance at 776 nm was 
from the NIR dye alone. There were no significant shifts in 
spectra between the free and conjugated dye (Fig. 3c). Protein 
concentrations for multiple reactions were also determined by 
Bradford assay. The reaction was reproducible, and despite 
manipulation of experimental parameters, UV-Vis spectroscopy 
showed the NIR dye drug-to-antibody ratio  ((NIR)DAR) never 
exceeded 0.7. LC-MS was carried out on a Thermo-Scientific 
system, and the NIR-conjugated Fab was compared to the 
unconjugated Fab-alkyne, results demonstrated that the 
reaction had reached completion with a (NIR)DAR of 1. The LC-
MS showed a single product peak with an observed mass of 
48951 Da, within accepted limits when 
 
Fig 3. Characterisation of the imaging agent; Fab-NIR. Samples of the NIR dye-Fab 
taken throughout the conjugation and purification process and ran on non-
reducing SDS-PAGE; Gels were Coomassie stained for protein (A) after imaging for 
NIR fluorescence (B). Unconjugated dye (seen at the dye front with the 10 kDa 
marker) was removed from the final product and any dye remaining was 
covalently bound. Fab-NIR was analysed by UV-Vis spectroscopy (C) shown 
overlayed with the spectrum of free NIR dye (dotted red) to show lack of shifts in 
spectra between the free and conjugated dye. 
compared to the expected mass of 48954 Da (Fig. 4). It is likely 
that dye interactions with the protein surface are adversely 
affecting the dye extinction coefficient, leading to an under-
estimation by UV-Vis spectroscopy. 
A pure and characterised NIR fluorescent trastuzumab fab 
molecule was produced with a stable covalently bound NIR dye 
at 1:1 stoichiometry. The addition of the NIR dye to our 
theranostic complies with modern homogenous antibody drug 
conjugate production methods.  
Formation of the Fab-NIR-PS theranostic conjugate  
Conjugation of photosensitisers to antibodies and antibody 
fragments is technically challenging; it has been previously 
shown that PS insolubility can (negatively) affect conjugate 
pharmacokinetics, conjugation efficiency and hinder 
purification of non-covalently bound free PS after 
conjugation44,46,55. In order to demonstrate a clear proof-of-
concept, a well-characterised and studied PS called chlorin e6 
(Ce6) was selected. Chlorin e6 has a high singlet oxygen 
quantum yield and a strong absorption at around ~660 nm, 
away from the absorption peak of the NIR dye ~780nm, 
together with relatively high water solubility48.  
Conjugation of chlorin e6 to the Fab-NIR fragment was 
initially attempted using in situ carbodiimide (EDC) / N-
hydroxysuccinimide (NHS) mediated chemistry between the 
carboxyl groups on the Ce6 and primary amine lysine residues 
on the antibody. However, cross-linking was a major side- 
reaction reducing both the purity and yield of the final 
conjugate as well as significantly reducing binding of the 
antibody to the antigen. Cross-linking was most likely caused by 
either excess EDC coupling agent or by the over-activation of 
more than one carboxylic acid group on the Ce6 molecule. Our 
data suggested that it was over activated Ce6 which was 
 
 
Fig 4. LC-MS characterisation of trastuzumab Fab-alkyne pre conjugation and 
trastuzumab Fab-NIR post conjugation on a Thermo Scientific system LC-MS shows 
a NIR dye conjugated product. The expected mass increase of 1197 Da between 
the samples matches the mass of the NIR-Dye without counter-ions (1200 Da). LC-
MS data non-deconvoluted (A) and deconvoluted (B). 
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responsible for the cross linking, therefore, reduced reaction 
times and excess NHS led to a reduction in protein cross-linking, 
although not to an acceptable level. 
To overcome protein cross-linking during the in situ 
procedure, we developed a method for chlorin e6 conjugation 
via the pre-formation of an anhydride ring between two 
carboxylic acid groups on the Ce6 molecule. This means 
reactions can be carried out without the need for a 
carbodiimide crosslinker and reduces the three reactive groups 
on Ce6 to one so cross-linking reactions should not be able to 
occur. This molecule was described previously as a temporarily 
formed molecular intermediate in the synthesis of talaporfin 
but has not to our knowledge ever been used in bio-
conjugation56. Chlorin e6 anhydride was prepared through a 
modified and improved procedure (supplementary data) and 
reaction with exposed epsilon-amines on the lysine side chains 
of the Fab fragment should result in ring opening and covalent 
amide bond formation. A similar reaction has been reported for 
a DOTA-anhydride with trastuzumab57.  
Samples of the purified theranostic antibody–drug 
conjugate ‘Fab-NIR-PS’ were analysed by SDS-PAGE. 
Photosensitisers are inherently fluorescent so the gel was 
imaged for NIR dye and PS fluorescence before fixing and 
staining (Fig. 5a–c). Almost all unconjugated PS was removed by 
desalting. A proportion of highly conjugated and aggregated 
antibody in which NIR fluorescence was quenched was also 
removed during the purification process. 
To determine NIRdye, PS and protein concentrations within 
the conjugate, a diluted sample of the Fab-NIR-PS was analysed 
by UV-Vis spectroscopy using correction factors calculated from 
the free dyes and applied to any wavelengths where more than 
one molecule absorbed (Fig. 5d). Protein concentrations were 
also determined by Bradford assay. Based 
 
 
Fig 5. Characterisation of the theranostic agent; trastuzumab Fab-NIR-PS. Samples 
of the Fab-NIR-PS were taken throughout the conjugation and purification process 
run on non-reducing SDS-PAGE; gels were Coomassie stained for protein (A) after 
being imaged for PS fluorescence (B) and NIR fluorescence (C). Almost all 
unconjugated dye (seen at the dye front with the 10 kDa marker) was removed 
from the final product and the dye was covalently bound. Fab-NIR-PS was analysed 
by UV-Vis spectroscopy (D) shown overlayed with a spectrum of free PS (dashed 
blue) and free NIR dye (dotted red). The Ce6 peak at 402 nm only broadened upon 
conjugation but the 660 nm Ce6 peak red shifted (663 nm conjugate vs 654 nm 
free) and the NIR dye peak at 780 nm also red-shifted (787 nm conjugate vs 778nm 
free). 
on these measurements, an average PS drug-to-antibody ratio 
((PS)DAR) of 4.4 was obtained as an average over four 
independent batches (standard deviation between batches 
below 1), protein yield was always above 70%. When the 
material lost during purification was analysed by SDS-PAGE it 
was shown to contain insoluble Fab monomers with a higher 
conjugation ratio rather than cross-linked protein.  
Compared to the free dyes, the absorbance spectrum of the 
Fab-NIR-PS conjugates show peak broadening at ~400 nm and 
red-shifts at ~660 nm and ~780 nm suggesting the extinction 
coefficients are influenced by the protein environment. 
Conjugates were also diluted into final 6 M urea solutions and 
analysed by UV-Vis spectroscopy to see if unfolding the protein 
would resolve any shifts and allow more accurate UV-Vis 
spectroscopic analysis but no effect on the spectrum was 
observed.  
Spectroscopic analyses seemed to show that the (NIR)DAR 
dropped to 0.45 in the theranostic (Fab-NIR-PS) compared to 
0.7 in the dye alone conjugate (Fab-NIR). The absorption 
spectrum also showed red-shift in NIR dye peak absorption. This 
suggested that the extinction coefficient for the NIR dye had 
changed upon Ce6 conjugation rather than NIR dye has been 
released from the Fab-NIR dye conjugate. This is supported by 
the absence of free NIR dye on SDS-PAGE for the un-purified 
double conjugate (Fig. 4). It was not possible to analyse the  Fab-
NIR-PS with the current method of LC-MS due to complications 
caused by the mixture of species generated but it would be 
possible with a modified technique58. 
Conjugation to accessible lysine residues produces a 
heterogeneous product distribution around an average loading 
 
 
Fig 6. Fluorescent spectra of the double conjugate compared to free dye. Samples 
of Fab-NIR-PS, free NIR dye and free Ce6 were matched for their absorbance 
peaks. Fluorescent spectra were read for (A) the Ce6 dye (Ex 402 nm Em 660 nm) 
and (B) the NIR dye (Ex 776 nm Em 792 nm). Presented spectra were normalised 
to the maximal counts per second (CPS) in each sample. Fluorescent peaks were 
observed as shown and showed no significant shifts in emission spectra from 
either dye apart from around 400 nm for the Ce6. Both dyes can still be excited 
independently with limited cross-over of energy. Raw fluorescent values for 
comparable samples show loss of fluorescent efficiency is seen after conjugation 
for both the Ce6 (8% of free dye) and NIR dye (19% of free dye). 
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ratio. This average loading ratio can be changed by 
manipulation of the reaction conditions. When the reaction 
between Ce6-anhydride and Fab-NIR was optimised products of 
higher conjugation ratios (average (PS)DAR > 5) were either 
insoluble in aqueous solution at pH 7.4 or showed significantly 
reduced antigen binding. The addition of excipients failed to 
maintain solubility or was detrimental to purification. The 
reaction was therefore optimised for the highest loading 
efficiencies that could maintain their solubility in PBS pH 7.4 at 
4 °C. Further evaluation of excipients or the introduction of 
another solubilising chemical group on the hydrophobic side of 
the Ce6 tetrapyrrole ring may improve payload loading and 
solubility or higher (PS)DARs may be possible using antibody 
fragment frameworks optimised for high payload loading44. 
Using a pre-activated Ce6 molecule a theranostic antibody–ADC 
was synthesised with an average therapeutic (PS)DAR of 4. A 
product with the same specifications could be produced reliably 
and reproducibly between independent experiments. Although 
state-of-the-art conjugation techniques focus on homogeneous 
ADC production, all ADCs currently marketed and in late phase 
clinical trials are mixed product conjugates59. When conditions 
are controlled a predictable and quantifiable composition can 
be produced which can be accurately analysed by mass 
spectrometry techniques; examples of this in clinically relevant 
conjugates can be found from Immunogen and Genetech, these 
conjugates translate into predictable and well characterised 
pharmacokinetic data58,60–63. Trastuzumab emtansine has 
between 0 and 7 loaded drugs (average DAR of 4) this ADC is IgG 
based, the range of products produced with our Fab is predicted 





Fig 7. In vitro cell binding of trastuzumab Fab-NIR dye and trastuzumab Fab-NIR 
dye-PS. Binding was tested on the cell line OE19, a human oesophageal 
adenocarcinoma with high HER2 expression (A,C,E) and U87, a human 
glioblastoma cell line and control for HER2 negativity (B,D,F). Cell staining was 
carried out on ice with a sub cell surface saturation concentration of the primary 
antibody trastuzumab in one of three forms; un-conjugated (red), conjugated to 
NIR dye only (green) and conjugated to both NIR and PS (blue). This was followed 
by an excess of anti-Fab antibody conjugated to a FITC fluorophore so antibody 
binding could be directly measured by an increase in FITC fluorescence (A,B), cells 
were also measured for fluorescence from the NIR dye (C,D) and for fluorescence 
from the PS dye (E,F). 
Fluorescence characterisation of the theranostic agent 
In order to confirm that the two components could be 
activated independently, the fluorescence excitation and 
emission profiles of the Fab-NIR-PS were analysed (Fig. 6). There 
were no shifts in emission spectra from either conjugated dye 
when compared to free dye and both dyes could be excited 
independently. Transfer of energy was limited to a small 
amount from Ce6 to NIR dye, seen by a shift in the shoulder of 
the NIR excitation peak at ~660 nm and a fluorescence emission 
peak at ~790 nm when Ce6 was excited at 402nm. When 
absorbance spectra were matched at wavelengths for Ce6 and 
NIR excitation and the fluorescence output measured, loss of 
fluorescence efficiency was seen after conjugation for both the 
Ce6 (8% of free dye) and NIR dye (19% of free dye).  
HER2 specific NIR cellular imaging of the theranostic agent 
To establish if the NIR dye was sufficiently fluorescent for 
cell labelling and if there was any loss of antibody binding upon 
single payload NIR dye conjugation or double payload NIR-PS 
conjugation, flow cytometry was carried out to measure binding 
to HER2 positive OE19 cells (Fig. 7). Detection of the Fab 
molecule was carried out under sub cell surface saturation 
conditions previously validated to be on the linear region of the 
binding curve for this experimental setup. Any changes in 
binding efficiency are seen as shifts in fluorescent signal; no 
shifts were seen with the Fab-NIR compared to Fab only, a slight 
but insignificant shift in antibody binding was seen with the Fab-
NIR-PS suggesting PS are only slightly interfering with antigen-
epitope recognition. Any effect on kinetic binding constants 
could be quantified using isolated antigen and surface plasmon 
resonance (i.e. BiacoreTM).  Labelled cells could easily be 
detected through both NIR-dye and PS emission. Single colour 
controls were used to ensure there was no bleed-through 
between the three detection wavelength ranges once 
compensated appropriately. The reduction in NIR fluorescence 
between the single and double conjugate, despite equivalent 
cell binding, supports the argument that the NIR dye is 
quenched slightly by the Ce6 in the double conjugate. Cells 
negative for HER2 expression showed no binding of either 
conjugate. 
HER2 targeted PDT cytotoxicity of the theranostic agent 
To investigate the potential use of the conjugate for 
targeted PDT, HER2 positive and negative cells were incubated 
at 37 °C for 1 hour in the dark with either the theranostic 
agent (Fab-NIR-PS) or equivalent amounts of free Ce6 before 
exposure to a final dose of 5 J/cm2 of 670 nm light over 60 
seconds (Fig. 8 and Fig. 9). A much lower total light dose than 
used clinically (100–200 J/cm2) was applied because as light 
travels into any tissue it quickly loses energy due to the 
scattering and absorbing properties of the tissue. For this 
reason sub-picomolar cytotoxicities obtainable by high light 
dose are not relevant for in vivo translation. Instead presented 
here is the limit of lowest effective toxicity with low light 
dose.. Control samples showed no cytotoxicity of the drug 
without laser irradiation or from laser irradiation alone (Fig 8.). 
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Upon laser irradiation the theranostic agent exhibited dose 
dependent cytotoxicity for HER2 positive cells with an IC50 of 
1.8µM (Fig 8.). If the IC50 of Fab-NR-PS is calculated as 
concentration of Ce6 within the conjugate, i.e. the  the 4:1 
ratio of photosensitizer conjugation is taken into account the 
IC50 of the conjugate is 7.3 uM per3uM Ce6. Free unconjugated 
Ce6 has an IC50 of 15.5uM with the same cell line  (Fig9.) There 
was no observable cytotoxicity of Fab-NR-PS with the HER2 
negative cell line U87 whereas cytoxicity with the free 
unconjugated Ce6 in this line was IC50 = .9.1uM. The relative 
large error bars are to be expected due to small variations of 
light dose across the beam area, despite this when analysed 
with area under the curve analysis according to Cleves et al.64, 
the Fab-NIR-PS induced cytotoxicity was significantly (p=0.04) 
higher for HER2 positive cells than the HER2 negative cells (Fig 
9.). When the same analysis was carried out with the data with 
the free unconjugated PS there was no significant difference in 
cytotoxicity between the two cell lines (Fig 9.).  
Typically, targeted PDT agents demonstrate potencies in the 
high nanomolar to micromolar range, this is lower than other 
published ADCs due to the lower cytotoxicity of singlet oxygen 
compared to the highly potent payloads used in current ADCs, 
however, other PDT ADCs have led to significant tumour 
reduction in vivo, and have shown multiple dosing is well 
tolerated alongside a favourable side-effect profile 44,45,65. 
 
 
Fig 8. Dose dependent PDT based cytotoxicity of the Fab-NIR-PS in a HER2 positive 
cell line (A) controls are shown in (B). All experiments undergo the same PDT 
treatment; cells were exposed to various concentrations of the drug over one hour 
at 37 °C, cells are then washed twice prior to exposing cells to a 670 nm laser at 5 
J/cm2. Cell viability was measured 24 hours later via MTT assay. The IC50 of Fab-
NIR-PS at this light does in this cell line was 1.8 µΜ. Controls show no toxicity of 
Fab-NIR-PS or equivalent free Ce6 without light or toxicity from the laser alone. 
Based on our own experience the cytotoxicity is within a 
range that can affect in vivo tumour growth if the PK, 
vasculature and immune parameters also important for 
effective PDT are in place. Based on this we would expect our 
Fab-NIR-PS to have anti-tumour activity in preclinical models. 
Conclusions 
Conjugation of two different optically-active moieties, a 
near-infrared imaging dye at 790 nm and a 670 nm laser 
activated photodynamic therapy drug to a trastuzumab Fab was 
shown to produce an effective and promising theranostic 
antibody–drug conjugate. The theranostic agent retained 
binding and was selective for its target in vitro as demonstrated 
by NIR imaging and antigen-specific cytotoxicity. With further 
development, we believe this theranostic agent shows potential 
as an adjunctive therapy for HER2 positive OGA. 
 
 
Fig 9. Dose dependent PDT based cytotoxicity of Fab-NIR-PS (B) compared to free 
PS (A) in HER2 positive and HER2 negative cell lines. Controls for the HER2 negative 
line are shown in (C). Data is presented as ‘concentration of Ce6 within the 
theranostic drug’ so it can be better compared with free drug. All experiments 
undergo the same PDT treatment; cells were exposed to various concentrations 
of the drug over one hour at 37 °C, cells are then washed twice prior to exposing 
cells to a 670 nm laser at 5 J/cm2. Cell viability was measured 24 hours later via 
MTT assay. Fab-NIR-PS was shown to be significantly more cytotoxic for HER2 
positive cells than HER2 negative cells (p=0.04), with the free PS there was no 
significant difference in cytotoxicity between HER2 positive cells than HER2 
negative cells. 
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Experimental 
LC-MS: was performed on protein samples using either an 
Agilent system or a Thermo Scientific system; both consisted of 
a uPLC column: Hypersil Gold C4 1.9 μm, 2.1μm × 50 μm 
connected to MSQ Plus Single Quad Detector (SQD) with the 
following parameters. Agilent system; Wavelength: 254 nm. 
Mobile Phase: 95:5 Water:MeCN (0.1% formic acid) to 5:95 
Water:MeCN (0.1% formic acid) gradient over 7-20 min. Flow 
Rate: 0.4 mL/min. MS Mode: ES+. Scan Range: m/z = 500–2400. 
Scan time: 1.0 s. Data obtained in continuum mode. The 
electrospray source of the MS was operated with a capillary 
voltage of 3.5 kV and a cone voltage of 35 V. Nitrogen was used 
as the nebulizer and desolvation gas at a total flow of 650 L/h. 
Ion series were generated by integration of the total ion 
chromatogram (TIC) over the 2.8–3.3 or 4–5 min range. Total 
mass spectra for protein samples were reconstructed from the 
ion series using MassLynx V4.0 SP4 software. Thermo Scientific 
system; Wavelength: 254 nm. Mobile Phase: 99:1 Water (0.1% 
formic acid): MeCN (0.1% formic acid) to 1:9 Water (0.1% formic 
acid): MeCN (0.1% formic acid) gradient over 4 min. Flow Rate: 
0.3 mL/min. MS Mode: ES+. Scan Range: m/z = 100 – 2000. Scan 
time: 1.5 s. Data obtained in continuum mode. The electrospray 
source of the MS was operated with a capillary voltage of 3.5 kV 
and a cone voltage of 50V. Nitrogen was used as the nebulizer 
and desolvation gas at a total flow of 600 L/h. Total mass spectra 
for protein samples were reconstructed from the ion series 
using the pre-installed ProMass software using default settings 
for large proteins in m/z range 500–2000. 
SDS-PAGE: Samples diluted into pH6.8 Tris-HCl loading buffer 
with final concentration of 2% SDS and 10% glycerol without 
reducing agents or tracking dyes and boiled for 5 minutes at 70-
100 °C. Gels were hand cast 1 mm gels with a discontinuous 
buffer system containing 0.1% APS and 0.1% TEMED to 
polymerise; Resolving gel: 12% acrylamide/bis 0.1% SDS, in 
0.37 M Tris-HCl pH8.8. Stacking gel: 4% acrylamide/bis 0.1% 
SDS, in 0.12 M Tris-HCl pH6.8. Samples were loaded at 2 μg 
protein alongside a marker (Thermo 26619). Gels ran at 30 mA 
per gel until bands well resolved in 1X running buffer (0.25M 
Trisma base + 2.5 M glycine + 0.1% SDS). Un-stained gels were 
imaged for fluorescence using a CCD camera flat bed imager 
(G:BOX CHEMI HR1.4, Syngene) and long pass filters (Horiba); 
NIR dye (Ex 720–763 nm, Em780LP), Photosensitiser (Ex 450–
485 Em:650LP). Gels were then fixed and stained with 0.1% 
Coomassie Brilliant Blue G in a 10% acetic acid 40% methanol 
buffer.  
UV-Vis spectroscopy; Read using a Lambda 25 (Perkin Elmer) in 
a micro volume 1cm path length quartz cuvette, samples diluted 
1:20 into PBS (pH7.4). Spectra normalised to 900 nm and 
solvent background removed. Concentrations were calculated 
using the following equation A = εlc where A is absorbance of 
the sample, ε = molar absorptivity, l = path length in cm and c = 
concentration in molar. Molar extinction coefficient (M-1 cm-1) 
were calculated in PBS pH 7.4 as follows; trastuzumab FAB-
alkyne 280 nm ε = 68590, NIR dye 280 nm ε = 5827, 402 nm ε = 
0, 776 nm ε = 188179, Ce6-anhydride 280 nm ε = 9816, 402 nm 
ε = 81020. Molecular weights (Da) calculated as follows; 
trastuzumab FAB-alkyne = 47786, NIR dye = 1269 and Ce6-
anhydride = 579.   
Bradford Assay: Samples were diluted 1:25 into Bradford 
reagent (Sigma B6916) in a 96 well plate, shaken (350 rpm) for 
5-10 minutes at room temperature then measured at 630 nm 
on a ELx800 Absorbance Microplate reader (BioTek). A standard 
curve of BSA was included on each plate and read 
simultaneously. BSA and trastuzumab Fab were shown to create 
identical standard curves and samples were loaded at a 
concentration below which NIR or PS dye would contribute to 
absorbance at 630 nm within the assay, previously calculated. 
Production of reduced trastuzumab Fab: To prepare 
trastuzumab-F(ab’)2 immobilized pepsin (0.6 mL) was washed 
with digestion buffer (20 mM sodium acetate trihydrate, pH 3.1) 
four times and trastuzumab (Roche) (2 mL, 6.47 mg/mL in 
digestion buffer) was added. The mixture was incubated for 5 h 
at 37 ºC whilst shaking (1100 rpm). Resin was separated from 
the digest using a filter column, and washed with digest buffer 
(50 mM phosphate, 1 mM EDTA, 150 mM NaCl, pH 6.8) three 
times. The digest was combined with the washes and the 
volume adjusted to 2 mL. Immobilized papain (2 mL, 0.25 
mg/mL) was activated with 10 mM DTT (in digest buffer: 50 mM 
phosphate, 1 mM EDTA, 150 mM NaCl, pH 6.8) whilst shaking 
(1100 rpm) for 1 h at 37 °C. Resin was washed with digest buffer 
(without DTT) four times and the 2 mL of trastuzumab-F(ab’)2 
added. The mixture was incubated for 48 h at 37 °C whilst 
shaking (1100 rpm). Then, resin was separated from the digest 
using a filter column, and washed with BBS (25 mM sodium 
borate, 25 mM NaCl, 1 mM EDTA, pH 8.0) three times. The 
digest was combined with the washes and the buffer was 
exchanged completely for BBS using diafiltration columns (GE 
Healthcare, 10 kDa MWCO) and the volume adjusted to 2 mL. 
To affect reduction of the interchain disulfide TCEP (240 µL, 6.5 
mM) was added to a solution of Fab fragment (8 mL, 65 μM, 3.1 
mg/mL in 25 mM sodium borate, 25 mM NaCl, 1 mM EDTA, pH 
8.0) and incubated for 1.5 h at 37 °C.  
Production of trastuzumab Fab Alkyne: For chemical synthesis 
of N-propargyl-3,4-dibromomaleimide see the supplementary 
data or as published50. To effect re-bridging of the interchain 
disulphide N-propargyl-3,4-dibromomaleimide ( 50 µL per mL of 
reduced trastuzumab Fab, 6.5 mM solution in DMF) was added 
to a solution of reduced trastuzumab Fab fragment (65 μM, 3.1 
mg/mL in 25 mM sodium borate, 25 mM NaCl, 1 mM EDTA, pH 
8.0). After 1 h at 20 °C, the excess N-propargyl-3,4-
dibromomaleimide was removed by repeated ultrafiltration (GE 
Healthcare, 10 kDa MWCO) into fresh buffer (PBS, pH 7.4).  
Production of trastuzumab Fab NIR imaging agent (Click 
chemistry): Trastuzumab Fab-alkyne was 0.22 µm spin filtered, 
then desalted (7 kDa MWCO Zeba) into 0.22 µm filtered PBS pH 
7.4. For a 500 µL reaction volume; trastuzumab Fab-alkyne was 
diluted to a final concentration of 65 μΜ in PBS (pH 7.4) 
containing final concentrations of tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA) (605 μM), CuSO4 
(121 μM) and aminoguanidine·HCl (5 mM). The THPTA and 
CuSO4 (stocks in deionised water stored at 4 °C) were premixed 
with each other at a 5:1 ratio just before use, 
aminoguanidine·HCl made up fresh in deionised water just 
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before use. To this mixture the azide containing molecule (Licor 
IR Dye 800CW Azide Infrared Dye Cat;929-60000) was added at 
12 equivalents to the alkyne (final concentration 800 μM) and 
final DMSO at 5% (v/v). Dye stock in anhydrous DMSO stored in 
the dark at -20 °C. Sodium ascorbate added last to the mixture 
(final concentration 4.5 mM, made up fresh in deionised water 
just before use). Reaction mixture incubated in a closed 
eppendorf in the dark on a flat bed shaker (125 rpm) at 37 °C 
overnight (~20 h). The sample was then subjected to centrifugal 
force to remove any precipitated material (10,000 g, 2 minutes) 
and filtered through a 0.22 μm filter. Excess reagents were 
removed by desalting (7 kDa MWCO Zeba) into fresh buffer 
(PBS, pH 7.4).  
Production of trastuzumab Fab NIR-Ce6 theranostic agent 
(Anhydride chemistry): For chemical synthesis of chlorin e6-
anhydride (Ce6-Anhydride) see supplementary data. Ce6-
anhydride (Antikor Biopharma) was stored as a solid at 4 °C in 
the dark under vacuum in a desiccator. The anhydride is 
hydrolysed over time in aqueous solution to its open ring form. 
Inactivated Ce6 (Medkoo Biosciences Cat. 500410) was stored 
in the dark at -20 °C. Handling of the photosensitive drugs and 
subsequent conjugates was whereever possible carried out 
under dim light conditions. At least 24 hours prior to reaction 
the Ce6-anhydride was made up at 20 mg/mL in anhydrous 
DMSO, snap frozen and stored at -20 °C. The drug could be used 
reliably in this form up to a week after it was frozen. For a 700 
μL reaction volume; trastuzumab Fab-NIR dye was diluted to a 
final concentration of 20 μΜ in PBS (pH 7.4). To this the Ce6-
anhydride was added at 20 equivalents to the protein (final 
concentration 400 μΜ) and final DMSO at 20%. Reaction 
mixture incubated in a closed eppendorf in the dark on a flat 
bed shaker (125 rpm) at 37 °C for 2 hours. The sample was then 
subjected to centrifugal force to remove any precipitated 
material (10,000 g, 2 minutes) and filtered through a 0.22 um 
filter. Excess reagents were removed by desalting (7kDa MWCO 
Zeba) into fresh buffer (PBS, pH 7.4). 
Fluorescent spectral analysis: Samples were diluted in PBS pH 
7.4 into a small volume quartz cuvette to ensure peak 
absorbance was below 0.25 absorbance units and absorption 
for the excitation wavelength was matched between free and 
conjugated dye within 0.05 absorbance units (Agilent 8453 
spectrophotometer). The cuvette was transferred to the 
spectrofluorometer (Horiba Jobin Yvon Fluoromax-4) and 
maintained at 20–22 °C. The emission spectra were corrected at 
each wavelength for the sensitivity of the detector and the 
excitation spectra were corrected at each wavelength for the 
lamp intensity (FluorEssence) and the second harmonic. Spectra 
were normalised to the maximal counts per second (CPS) in 
each sample. Where samples are presented together or 
compared all read settings were identical including excitation 
wavelength, em/ex slits and integration time of the signal. 
In vitro cell culture; OE19 cells were obtained from the ECACC 
May 2014 and U87-MG were a kind gift from Dr M. P. 
Deonarain, Imperial College London, 2010. All lines were 
cultured according to ECACC guidelines. Cells were confirmed 
mycoplasma free and kept within a 20 passage range.  
Flow cytometry: Cells were detached with Accutase, and 
200,000 cells per sample were washed and incubated in 50 μL 
on ice with various concentrations of trastuzumab. After 1 hour 
cells were washed and exposed to 300 nM α-Human IgG (Fab 
specific) FITC conjugate (SIGMA F5512) on ice for 30 minutes 
before two final washes. All steps carried out in FC buffer; PBS 
+ 2% FCS + 1 mM EDTA. Flow cytometry was carried out on a 
Beckman-Coulter Cyan ADP, FITC detection channel; (Ex 488 nm 
Em 510–550 nm), NIR dye detection channel; (Ex 635 nm 
Em750LP), PS detection channel; (Ex 635 nm Em655–675). Data 
was taken from the fluorescent signal of 10,000 cells gated to 
exclude, doublets, aggregates and debris. Data was analysed 
and quantified using the geometric mean of the curve using 
Flowing Software Version 2.5.1 (Perttu Terho, Turku Centre for 
Biotechnology, Finland). For analysis of the ADCs trastuzumab 
antibodies were incubated at 50 nM because this was shown to 
be just under cell surface saturation of OE19 cells (Fig. 2). 
Photodynamic therapy (PDT): Cells were plated in clear 
bottomed black walled 96 well plates at 25,000 cells (OE19) or 
12,000 cells (U87) per well, plates for U87 cells were pre-coated 
with attachment factor (cell systems 4Z0-210). Cell number was 
previously calibrated to ensure endpoint signal was not 
saturated and cells were not over-confluent. The following day 
media was replaced with 100 μL media containing experimental 
compound at varying concentrations. Plates were protected 
from light and incubated at 37 °C and 5% CO2 for one hour, cells 
were washed twice with PBS and returned to 200 μL media 
before being exposed to a 670 nm Laser (Hamamatsu LD670C) 
at a dose of 5 J/cm2 over 60 seconds at 80 mW/cm2. Cells not 
irradiated were protected by a cardboard shield, plates were 
protected from light and returned to the incubator. Light was 
delivered via fibre optic / frontal light distributor (model FD-1 
Medlight S.A SN FD1-1345) and calibrated for exact energy 
delivery (Gentec TDM-300 / PSV-3103). 24 h later, media was 
replaced with 200 μL MTT reagent (Sigma-Aldrich M5655) at 0.5 
mg/mL in FCS free cell culture media. (MTT is a tetrazolium salt 
based assay and measures cell viability by the detection of 
cellular reducing equivalents such as NADH that are produced 
during normal cellular metabolism.) Plates were protected from 
light and incubated at 37 °C and 5% CO2 for three hours, MTT 
media was then replaced by 100 μL DMSO and shaken (350 rpm) 
for 10–15 minutes until all crystals had dissolved before the 
absorbance at 490 nm was measured on a ELx800 Absorbance 
Microplate reader (BioTek). For IC50 Equation fitted using sigma 
plot; four Parameter Logistic Curves with equation;  f1 = min + 
(max-min)/(1 + (x/EC50)^(-Hillslope)), constrained min=0, 
max=100. 
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